Twirla ® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX) (Agile or the Company), a ...
This month, Agile Therapeutics, Inc. AGRX announced partnerships with FPA Women’s Health and vitaCare Prescription Services that will expand access to Twirla® (levonorgestrel and ethinyl estradiol) ...
FPA Women’s Health is the largest independent family planning service network in the United States, and the Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now the exclusive patch ...
CHARLESTON, S.C., June 30, 2025 /PRNewswire/ -- Afaxys, Inc., a Public Benefit Corporation and first-of-its kind socially conscious healthcare company focused on serving public health professionals ...
Transdermal estradiol patches — the same ones used to curb menopause symptoms in women — are an effective alternative to luteinizing hormone–releasing hormone agonists to lower PSA levels in men with ...
The proportion of patients achieving a prostate-specific antigen nadir less than or equal to 0.2 ng/ml was exactly the same for patients treated with transdermal estradiol patches and those treated ...
The Company expects to submit the New Drug Application for Xulane Lo in the second half of 2025. A low dose combination hormonal patch was found to be effective for pregnancy prevention based on ...
Transdermal estradiol patches show similar PSA response to LHRHa when combined with ARPIs in metastatic prostate cancer. The STAMPEDE trial indicates tE2 patches offer a favorable safety profile, ...
EE: Ethinyl estradiol; LNG: Levonorgestrel; OC: Oral contraceptive; RR: Relative risk; VTE: Venous thromboembolism. Transdermal contraceptive patches provide a more convenient delivery system for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results